Aim of this european meeting is to discuss the ongoing implementation and to forecast systemic consequences of the HTA Regulation (EU) 2021/2282, which will come into force on January 2025.

It will bring together in situ, leading figures from European and national HTA bodies as well as socio-economic players including European patients, physicians and entrepreneurs organizations, for direct, convivial, fruitful interactions.

Attendees are advanced students and academic researchers, national regulators, public & private decision makers operating in the fields of HTA and public governance, pharmaceutical law and regulatory affairs, market access.

This meeting is a pilot – the first of a series focusing on our Nations and Union transformations and future performance facing existential challenges … and opportunities ?

Biographies of keynote speakers & other documents will be sent to registered participants.

150 seats – non-hybrid event – no registration fees
motivated application – full english, no translation

APPLICATION LINKS ON THE EUROPEAN PARLIAMENT PLATFORM:

Academics	*EU & State bodies*	*Other Players*

In accordance with both HTA bodies and EP compliance rules, this conference is funded only by the university of Strasbourg, the university of Catania, and the Séminaires Strasbourg Berkeley Descartes, EU Transparency Register REG 646472092848-46.
Thanks to the staff of the School of Pharmacy Unistra, to the students from Med'Advice & CEPhI, to the journal Le Point & the European Parliament staff, for their kind support.

Photo credit: *elevation of the central part of the west facade, Strasbourg Cathedral, (extract) architectural drawing circa 1360 / 1370 (500 cm full height). Deposit of the Fondation Œuvre Notre-Dame to the Musée de l'Oeuvre Notre-Dame de Strasbourg. By Courtesy, Musées de Strasbourg, photo by M. Bertola.*



De l'humanisme rhénan du XVI[e] siècle Université de Strasbourg au campus européen du XXI[e] siècle.

Health Technology Assessment in Europe, Transformation, Performance ?

Conference – debate

European Parliament

Strasbourg

Friday, November 8, 2024
9:00 am to 5:30 pm

Séminaires Strasbourg – Berkeley – Descartes

avec Le Point

HTA in Europe – Transformation, Performance ?

08h30 – Welcome in room

09h00 – Address, welcome to the European Parliament

Fabienne KELLER, Member of the European Parliament, & Quaestor, European Parliament

Pr. Frédérique BERROD, Vice-présidente, University of Strasbourg / EUCOR

09h10 – How to end « *multiple and divergent requests for data* » ?

Pr. Filippo DRAGO, *Chairman CERD, University of Catania, Italy*

RT 1 – From EUnetHTA, to the Health Technology Assessment Regulation : implementing measures update

Anne WILLEMSEN, Senior Advisor, Dutch National Healthcare Institute (ZIN), The Netherlands & Co-chair of the Joint Clinical Assessment Subgroup, HTACG

Dr. Leslie PIBOULEAU, Senior policy officer, DG SANTE, European Commission, Brussels

Judith FERNANDEZ, D-Director, HTA Department in charge of international affairs, Haute Autorité de Santé, France

---

RT 2 – Joint Clinical Assessment : issues, choices and methodological challenges ?

Moderator Judith FERNANDEZ, *D-Director, HTA Department in charge of international affairs, HAS, France*

Dr. Roisin ADAMS, Head, HTA Strategy and External Engagement, National Centre for PharmacoEconomics, Ireland & Chair, European HTA Coordination Group (HTACG)

Dr. Paul de BOISSIEU, Project Manager, Drug Assessment Division, Haute Autorité de Santé (HAS) France & Chair of the Joint Clinical Assessments Subgroup, HTACG

Dr. Beate WIESELER, Head, Department of drug assessment, IQWIG, Germany & Chair of the Methodological and Procedural Guidance Subgroup, HTACG

Anne WILLEMSEN, Senior Advisor, Dutch National Healthcare Institute (ZIN), The Netherlands & Co-chair of the Joint Clinical Assessment Subgroup, HTACG

12h00 - Lunch-Buffet, Atrium

13h30 – What could the national « *due consideration* » to JCA mean ?

Pr. Francis MEGERLIN*, Head Séminaires SBD, University of Strasbourg / EUCOR*

RT 3 – National reception of Joint Clinical Assessments : what impact for decision support ?

Moderator *Dr. Heiner HAUG,* *Chairman, HTA Europe Committee Leem & Astrazeneca, France*

Dr. Roisin ADAMS, Head, HTA Strategy and External Engagement, National Centre for PharmacoEconomics, Ireland & Chair, European HTA Coordination Group (HTACG)

Pr. Pierre COCHAT, Président, Commission de la Transparence, Haute Autorité de Santé, France

Dr. Pierluigi RUSSO, Executive Director, Agenzia Italiana del Farmaco (AIFA), Italy

Pr. Rui SANTOS IVO, President of the Executive Board, National Authority of Medicines and Health Products (Infarmed), Portugal

Dr. Michal STAŇÁK, founding Director, National Institute for Value and Technologies in Health Care (NIHO), Slovakia

Dr. Beate WIESELER, Head, Department of drug assessment, Institut for Quality and Efficiency in Health Care (IQWIG), Germany & Chair of the Methodological and Procedural Guidance Subgroup, HTACG

RT 4 – Joint Clinical Assessments : towards renewed socio-economic interactions ?

Moderator Agnieszka BUELENS*, Head DATAETHICS, University Medical Center Goettingen*

Pr. Elisabeth de VRIES, University Medical Centre Groningen, Groningen, the Netherlands & Cancer Medicines committee, European Society for Medical Oncology (ESMO)

Dr. Ansgar HEBBORN, Chair, HTA Working Group, European Federation of Pharmaceutical Industries and Associations (EFPIA)

Marie-Laure HECQUET, Policy advisor, Director Office, European Directorate for the Quality of Medicines & Healthcare (EDQM), Council of Europe

François HOUŸEZ, Director of Treatment Information and Access, European Organisation for Rare Diseases (EURORDIS)

Dr. Alexander NATZ, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

Julie SPONY, Policy Officer, European Patient Forum (EPF)

Next Steps ? ***Francis MEGERLIN & Filippo DRAGO***

17h30 – Au revoir